CDK4/6 inhibitors are the key to accurate diagnosis, classification and treatment of early breast cancer

TextThree Gold

Recently, Eli Lilly announced that the National Medical Products Administration (NMPA) has approved a new indication for Abemaciclib (trade name: Weizhe), a new anti-tumor drug

PART.

Breast cancer has previously been classified into different subtypes based on the levels of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) expressed by breast cancer

Although the latest epidemiological survey shows that the decline in breast cancer mortality has slowed year by year, its long-term risk has not decreased significantly

Several studies have confirmed that CDK4/6 inhibitors combined with ET can significantly improve the prognosis of advanced breast cancer patients with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-)

CDK4/6, cyclin-dependent kinase 4/6, is one of the important regulators in the process of mitosis and is closely related to the occurrence and development of various cancers

CDK inhibitors include INK4 family and CIP/KIP family proteins in humans

In addition to Abemaciclib, Palbociclib, and Ribociclib, which are also used as breast cancer treatments, Palbociclib or Ribociclib in combination with letrozole are the first-line treatment options for breast cancer

PART.

In February 2018, the FDA re-approved abeciclib in combination with an aromatase inhibitor as an initial endocrine therapy for HR+, HER2- postmenopausal women with advanced or metastatic breast cancer

The approval of this new indication is based on the results of a randomized, open-label, multicenter Phase III clinical trial, monarchE

According to the results of the study, the combination therapy of abeccil and ET can significantly improve the invasive disease-free survival (IDFS) of patients with HR+ and HER2- high-risk early breast cancer

PART.

With the demonstrated role of CDK4/6 inhibitors in the treatment of high-risk early breast cancer, accurate diagnosis, typing and treatment have become the key to the future
.

References:

1.
Eli Lilly's official website

2.
C.
Louwrens Braal, Elisabeth M.
Jongbloed, Saskia M.
Wilting, Ron HJ Mathijssen, Stijn LW Koolen, and Agnes Jager.
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences[J] Drugs.
2021; 81(3): 317–331.

3.
N.
Harbeck et.
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study[J].
Ann Oncol.
2021 Sep 29;S0923-7534(21)04494 -X.